[Prevalence of hepatitis C virus in poly-transfused patients with hematologic and oncologic diseases].
Patients with hematological and oncological diseases often require intensive, supportive hematotherapy due to the underlying disease or chemo-/radiotherapy. As a consequence, they had an increased transfusion-associated risk of hepatitis C virus infections (non-A, non-B-posttransfusion hepatitis) until 1989-1990, when specific and sensitive HCV antibody tests became available. This is confirmed by our study of 'first' and 'second' generation (1.0 and 2.0) anti-HCV EIAs against structural and non-structural (NS) antigen-determinants. Ten of 101 patients (10.9%) were anti-HCV positive in 2.0 tests. HCV antibodies were detected more often by 2.0 EIAs and the new HCV-immunoblot (4-RIBA), than by 1.0 EIAs. In this respect, the patients' serological HCV profile differs from that of healthy blood donors, which display a prevalence of NS-antibodies.
Gutensohn
K
K
Abt. Onkologie und Hämatologie, Univ.-Krankenhaus Hamburg-Eppendorf.
Knödler
B
B
Zeller
W
W
Krüger
W
W
Eckardt
N
N
Hossfeld
D K
DK
Kühnl
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D000956:Antigens, Viral / Q000276:immunology; D016913:Blood Component Transfusion; D001803:Blood Transfusion; D005260:Female; D006402:Hematologic Diseases / Q000276:immunology / Q000628:therapy*; D006508:Hepatitis Antibodies / Q000032:analysis; D006526:Hepatitis C / Q000175:diagnosis / Q000276:immunology / Q000635:transmission*; D018936:Hepatitis C Antigens; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D000956:Antigens, Viral; D006508:Hepatitis Antibodies; D018936:Hepatitis C Antigens